Buy Naropin solution 5 mg/ml polypropylene ampoules
  • Buy Naropin solution 5 mg/ml polypropylene ampoules

Naropin® [Ropivacaine]

AstraZeneca
1573 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$97.94
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Naropin - the first local anesthetic of the long-acting amide type, which is a pure enantiomer. It has both anesthetic and analgesic effects.

High doses of the drug are used for local anesthesia during surgical interventions, low doses of the drug provide analgesia (sensory block) with a minimal and not progressive motor block.

The duration and intensity of the blockade caused by ropivacaine, the addition of adrenaline does not affect. Reversibly blocking voltage-dependent sodium channels, prevents the generation of impulses at the end of the sensory nerves and conduction of impulses along the nerve fibers.

Like other local anesthetics, it can affect other excitable cell membranes (for example, in the brain and myocardium). If an excess amount of local anesthetic reaches the systemic circulation in a short period of time, signs of systemic toxicity are possible.

Signs of toxicity on the part of the central nervous system are preceded by signs of toxicity on the part of the cardiovascular system, as they are observed at lower plasma concentrations of the drug.

The direct action of local anesthetics on the heart includes a slower conduction, a negative inotropic effect and, in severe overdose, arrhythmias and cardiac arrest. Intravenous administration of high doses of ropivacaine leads to the same effects on the heart.

Intravenous infusions of ropivacaine to healthy volunteers showed its good tolerability. Indirect cardiovascular effects (lowering blood pressure, bradycardia) that may occur after epidural administration of ropivacaine are due to the resulting sympathetic blockade.

Indications

Local anesthesia:

  • epidural, incl. with cesarean section
  • conductor (including large nerves and plexuses),
  • infiltration,
  • relief of acute pain (including postoperative pain relief and pain relief of labor).

Composition

1 ml contains ropivacaine hydrochloride 5 mg

No customer reviews for the moment.

Write your review

Write your review

Naropin® [Ropivacaine]

Dosage and Administration

Naropin It should be used only by specialists with sufficient experience in conducting regional anesthesia, or under their supervision.

When selecting the dose of the drug should be based on clinical experience, taking into account the physical status of the patient.

In general, anesthesia for surgical interventions (for example, for epidural administration) requires higher doses and more concentrated solutions of the drug.

When anesthesia (for example, epidural administration for the relief of pain), lower doses and concentrations of the drug are recommended.

Adverse reactions

Unwanted reactions toNaropin similar to reactions to other local anesthetics amide type. They should be distinguished from the physiological effects arising from the blockade of sympathetic nerves during epidural anesthesia, such as a decrease in blood pressure, bradycardia, or effects associated with the administration of the drug, such as local nerve damage, meningitis, postfunctional headache, epidural abscess.

Side Effects of Local Anesthetics

From the central and peripheral nervous system

Possible neuropathy and dysfunction of the spinal cord (anterior spinal artery syndrome, arachnoiditis, horse tail syndrome), usually associated with the technique of regional anesthesia, and not with the effect of the drug.

As a result of accidental intrathecal administration of an epidural dose, a complete spinal block can occur.

Serious complications are possible with systemic overdose and unintentional intravascular administration of the drug (see the “Overdose” section).

Acute systemic toxicity

Naropin may cause acute systemic toxic reactions when using high doses or with a rapid increase in its concentration in the blood in case of accidental intravascular administration of the drug or its overdose (see the section “Overdose”).

The most common side effects

Various side effects of the drug were reported, the overwhelming majority of which were associated not with the effect of the anesthetic used, but with the technique of regional anesthesia.

Most often (> 1%) the following side effects were noted, which were regarded as having clinical significance regardless of whether a causal relationship was established with the use of anesthetic: decrease in blood pressure *, nausea, bradycardia, vomiting, paresthesia, fever , headache, urinary retention, dizziness, chills, increased blood pressure, tachycardia, hypoesthesia, anxiety.

Often

From the CCC: a decrease in blood pressure.

From the digestive tract: nausea.

Often

From the nervous system: paresthesia, dizziness, headache.

From the CCC: bradycardia, tachycardia, hypertension.

From the digestive tract: vomiting.

From the genitourinary system: urinary retention.

Are common: back pain, chills, fever.

Infrequently

From the nervous system: anxiety, symptoms of toxicity from the central nervous system (convulsions, major seizures, paresthesias in the perioral zone, dysarthria, numbness of the tongue, visual impairment, tinnitus, tremor, muscle cramps), hypoesthesia.

From the vascular system: fainting.

On the part of the respiratory system: shortness of breath, difficulty breathing.

Are common: hypothermia.

Seldom

From the CCC: arrhythmia, cardiac arrest.

Are common: allergic reactions (anaphylactic reactions, angioedema, urticaria).

Contraindications

  • hypersensitivity;
  • children's age up to 12 years (because there is a lack of a sufficient number of clinical observations).

Drug interactions

Enhances the toxic effect of other local anesthetics and drugs, the structure similar to local anesthetics amide type.

Pregnancy and Lactation

Carefully. Use for anesthesia or analgesia in obstetrics is justified.

Special instructions

Patients with severe liver disease need to reduce repeated doses. Avoid long-term use in conjunction with fluxamine.

Be careful when using vehicle drivers and people whose profession is related to increased concentration of attention.

Overdosage

Symptoms: visual and hearing impairment, hypotension, arrhythmia, dysarthria, increased muscle tone, muscle twitching, convulsions, loss of consciousness, hypoxia, hypercapnia, respiratory failure or stopping.

Treatment: stopping the administration of the drug, maintaining adequate oxygenation, stopping convulsions and convulsions (intravenous thiopental 100–120 mg or diazepam 5–10 mg), normalization of blood circulation, correction of acidosis; with the development of hypotension and bradycardia - IV the introduction of 5-10 mg of ephedrine (possibly again after 2-3 minutes).

  • Brand name: Naropin
  • Active ingredient: Ropivacaine
  • Dosage form: Injection.
  • Manufacturer: AstraZeneca
  • Country of Origin: Great Britain

Studies and clinical trials of Ropivacaine (Click to expand)

  1. Liquid chromatographic bioanalytical determination of ropivacaine, bupivacaine and major metabolites
  2. Determination of ropivacaine and bupivacaine in human plasma by programmed temperature vaporiser-fast gas chromatography-mass spectrometry (PTV/fast GC/MS) utilising in-vial liquid-liquid extraction
  3. Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey
  4. Simultaneous determination of ropivacaine and antipyrine by high performance liquid chromatography and its application to the in vitro transplacental study
  5. Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column
  6. Synthesis of tritium labelled ropivacaine — A new potential local anesthetic
  7. Synthesis of carbon-14 labelled ropivacaine, a local anaesthetic agent
  8. Microextraction in packed syringe (MEPS) for liquid and gas chromatographic applications. Part II—Determination of ropivacaine and its metabolites in human plasma samples using MEPS with liquid chromatography/tandem mass spectrometry
  9. Crystal structure and physical properties of two polymorphs of ropivacaine HCl
  10. Quantification of ropivacaine and its major metabolites in human urine samples utilizing microextraction in a packed syringe automated with liquid chromatography-tandem mass spectrometry (MEPS-LC-MS/MS)
  11. Determination of ropivacaine and its metabolites in human plasma using solid phase microextraction and GC-NPD/GC-MS
  12. Determination of the free concentration of ropivacaine in plasma by packed capillary liquid chromatography: A comparison of ultrafiltration and microdialysis as sample preparation methods
  13. Use of heptakis(2,6-di-O-methyl)-β-cyclodextrin in on-line capillary zone electrophoresis-mass spectrometry for the chiral separation of ropivacaine
  14. Determination of free concentration of ropivacaine and bupivacaine in blood plasma by ultrafiltration and coupled-column liquid chromatography
  15. Validation of a capillary electrophoresis method for the enantiomeric purity testing of ropivacaine, a new local anaesthetic compound
  16. PIII-65Population pharmacokinetics of bupivacaine and ropivacaine in combined femoral-sciatic nerve block
  17. Liquid chromatography–electrospray mass spectrometry determination of free and total concentrations of ropivacaine in human plasma
  18. Column-switching HPLC–MS/MS analysis of ropivacaine in serum, ultrafiltrate and drainage blood for validating the safety of blood reinfusion
  19. Simultaneous determination of procaine, lidocaine, ropivacaine, tetracaine and bupivacaine in human plasma by high-performance liquid chromatography
  20. Development and validation of a LC method for the enantiomeric purity determination of S-ropivacaine in a pharmaceutical formulation using a recently commercialized cellulose-based chiral stationary phase and polar non-aqueous mobile phase
  21. Enantioselective total syntheses of ropivacaine and its analogues
  22. Determination of ropivacaine and its metabolites in patient urine: Advantage of liquid chromatography–tandem mass spectrometry over liquid chromatography–UV detection and liquid chromatography–mass spectrometry
  23. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine
  24. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors*

8 other products in the same category:

arrow_upward